$MTNB
Matinas BioPharma Holdings, Inc. Stock $mtnb

$mtnb Overview Financials Valuation SEC Filings Company Website

2017 Q2 Form 10-Q Financial Statement

#000114420417040982 Filed on August 08, 2017

Income Statement

Concept	2017 Q2	2016 Q4	2016 Q2
Revenue	$44.91K		$0.00
YoY Change			-100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development			$642.6K
YoY Change			-52.57%
% of Gross Profit
Depreciation & Amortization	$12.00K	$10.00K	$13.00K
YoY Change	-7.69%	0.0%	30.0%
% of Gross Profit
Operating Expenses			$1.620M
YoY Change			-34.64%
Operating Profit	-$3.976M		-$1.620M
YoY Change	145.42%		-32.54%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net	$8.663K		-$3.656K
YoY Change	-336.95%		33.53%
Pretax Income
YoY Change
Income Tax
% Of Pretax Income
Net Earnings			-$1.624M
YoY Change			-32.47%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share
COMMON SHARES
Basic Shares Outstanding	91.40M shares	58.05M shares	57.59M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2017 Q2	2016 Q4	2016 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$11.27M	$4.110M	$580.0K
YoY Change	1843.1%	27.24%	-91.23%
Cash & Equivalents	$11.27M	$4.110M	$578.3K
Short-Term Investments
Other Short-Term Assets	$480.0K	$460.0K	$200.0K
YoY Change	140.0%	39.39%	-9.09%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$11.74M	$4.570M	$770.0K
YoY Change	1424.68%	28.4%	-88.81%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.170M	$360.0K	$380.0K
YoY Change	207.89%	-4.69%	4.63%
Goodwill	$1.336M	$1.336M	$1.336M
YoY Change	0.0%	0.0%	-3.48%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$540.0K	$540.0K	$50.00K
YoY Change	980.0%	350.0%	-77.27%
Total Long-Term Assets	$6.060M	$5.250M	$4.790M
YoY Change	26.51%	8.32%	-3.85%
TOTAL ASSETS
Total Short-Term Assets	$11.74M	$4.570M	$770.0K
Total Long-Term Assets	$6.060M	$5.250M	$4.790M
Total Assets	$17.80M	$9.820M	$5.560M
YoY Change	220.14%	16.82%	-53.13%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$453.2K	$475.6K	$480.0K
YoY Change	-5.58%	-4.47%	-35.62%
Accrued Expenses	$731.7K	$829.7K	$850.0K
YoY Change	-13.92%	35.97%	150.12%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$120.0K	$0.00
YoY Change			-100.0%
Long-Term Debt Due	$20.00K	$10.00K	$10.00K
YoY Change	100.0%	0.0%	-66.67%
Total Short-Term Liabilities	$1.335M	$1.445M	$1.340M
YoY Change	-0.36%	28.02%	17.94%
LONG-TERM LIABILITIES
Long-Term Debt	$50.00K	$20.00K	$20.00K
YoY Change	150.0%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$50.00K	$20.00K	$20.00K
YoY Change	150.0%		-97.62%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.335M	$1.445M	$1.340M
Total Long-Term Liabilities	$50.00K	$20.00K	$20.00K
Total Liabilities	$2.592M	$2.666M	$2.567M
YoY Change	0.95%	14.26%	-20.52%
SHAREHOLDERS EQUITY
Retained Earnings	$43.64M	$35.18M	-$27.06M
YoY Change	-261.31%	-251.72%	42.2%
Common Stock	$9.194K	$5.817K	$5.760K
YoY Change	59.62%	1.71%	1.09%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$15.21M	$7.150M	$2.997M
YoY Change
Total Liabilities & Shareholders Equity	$17.80M	$9.816M	$5.565M
YoY Change	219.87%	16.78%	-53.09%

Cashflow Statement

Concept	2017 Q2	2016 Q4	2016 Q2
OPERATING ACTIVITIES
Net Income			-$1.624M
YoY Change			-32.47%
Depreciation, Depletion And Amortization	$12.00K	$10.00K	$13.00K
YoY Change	-7.69%	0.0%	30.0%
Cash From Operating Activities	-$3.730M	-$2.120M	-$1.100M
YoY Change	239.09%	90.99%	-50.45%
INVESTING ACTIVITIES
Capital Expenditures	-$790.0K		-$30.00K
YoY Change	2533.33%		-25.0%
Acquisitions
YoY Change
Other Investing Activities		$0.00	$0.00
YoY Change
Cash From Investing Activities	-$790.0K	$0.00	-$30.00K
YoY Change	2533.33%	-100.0%	-25.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-50.00K	0.000	30.00K
YoY Change	-266.67%	-100.0%	-99.29%
NET CHANGE
Cash From Operating Activities	-3.730M	-2.120M	-1.100M
Cash From Investing Activities	-790.0K	0.000	-30.00K
Cash From Financing Activities	-50.00K	0.000	30.00K
Net Change In Cash	-4.570M	-2.120M	-1.100M
YoY Change	315.45%	87.61%	-155.56%
FREE CASH FLOW
Cash From Operating Activities	-$3.730M	-$2.120M	-$1.100M
Capital Expenditures	-$790.0K		-$30.00K
Free Cash Flow	-$2.940M		-$1.070M
YoY Change	174.77%		-50.92%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2017Q2	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	18752	USD
CY2016Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	36237504	USD
CY2017Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	53045284	USD
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	35179710	USD
CY2017Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	43643467	USD
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	7149961	USD
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1444793	USD
CY2017Q2	us-gaap	Liabilities Current LiabilitiesCurrent	1335151	USD
CY2016Q4	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	16446	USD
CY2017Q2	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	51362	USD
CY2016Q4	us-gaap	Common Stock Value CommonStockValue	5817	USD
CY2017Q2	us-gaap	Common Stock Value CommonStockValue	9194	USD
CY2017Q2	us-gaap	Stockholders Equity StockholdersEquity	15208259	USD
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	9816341	USD
CY2017Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	17799913	USD
CY2016Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	155610	USD
CY2017Q2	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	155377	USD
CY2017Q2	us-gaap	Liabilities Liabilities	2591654	USD
CY2016Q4	us-gaap	Liabilities Liabilities	2666380	USD
CY2017Q2	us-gaap	Goodwill Goodwill	1336488	USD
CY2016Q4	us-gaap	Goodwill Goodwill	1336488	USD
CY2017Q2	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	3017377	USD
CY2016Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	3017377	USD
CY2017Q2	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	11758	USD
CY2017Q2	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	1205141	USD
CY2016Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	11485	USD
CY2016Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	1205141	USD
CY2017Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	453220	USD
CY2016Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	829724	USD
CY2017Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	731671	USD
CY2016Q4	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	9936	USD
CY2017Q2	us-gaap	Notes Payable Current NotesPayableCurrent	0	USD
CY2016Q4	us-gaap	Notes Payable Current NotesPayableCurrent	118046	USD
CY2017Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	119750	USD
CY2016Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	0	USD
CY2017Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-3976303	USD
CY2016Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-1620229	USD
CY2017Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	8663	USD
CY2016Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-3656	USD
CY2016Q2	us-gaap	Revenues Revenues	0	USD
CY2017Q2	us-gaap	Revenues Revenues	44906	USD
CY2017Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3967640	USD
CY2016Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1623885	USD
CY2017Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.04
CY2016Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.03
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4698934	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1564287	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3824468	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2293430	USD
	us-gaap	Operating Expenses OperatingExpenses	8523402	USD
	us-gaap	Operating Expenses OperatingExpenses	3857717	USD
	us-gaap	Net Income Loss NetIncomeLoss	-8463757	USD
	us-gaap	Net Income Loss NetIncomeLoss	-3868495	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-8463527	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-3857717	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-230	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-10778	USD
	us-gaap	Revenues Revenues	0	USD
	us-gaap	Revenues Revenues	59875	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-25205113	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3868495	USD
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.29
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.07
	mtnb	Warrants Conversions Inducements WarrantsConversionsInducements	16741356	USD
	mtnb	Warrants Conversions Inducements WarrantsConversionsInducements	0	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	26298	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	24800	USD
	us-gaap	Other Noncash Expense OtherNoncashExpense	1742	USD
	us-gaap	Other Noncash Expense OtherNoncashExpense	273	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	793471	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	1687690	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-105295	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-5076	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-21979	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-22382	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	163050	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-2636656	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-6759432	USD
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	0	USD
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	118046	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-2648684	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3226997	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	21696	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	14834367	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
CY2017Q1	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	13500000	USD
CY2017Q1	mtnb	Estimated Net Proceeds From Issuance Of Warrants EstimatedNetProceedsFromIssuanceOfWarrants	12700000	USD
CY2017Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	32227000	shares
CY2016Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	47521000	shares
CY2017Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	12700000	USD
CY2017Q1	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	15500000	USD
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	58159495	shares
CY2017Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	30966350	shares
CY2016Q1	mtnb	Capitalized Leasing Term CapitalizedLeasingTerm	P36M
CY2017Q2	mtnb	Undeclared Dividend UndeclaredDividend	559000	USD
CY2017Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	14800000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1688000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	794000	USD
CY2013Q4	us-gaap	Lessor Leasing Arrangements Operating Leases Term Of Contract LessorLeasingArrangementsOperatingLeasesTermOfContract	P7Y
CY2014Q2	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	12723	USD
CY2014Q2	mtnb	Increase Decrease In Lease Rental Expense IncreaseDecreaseInLeaseRentalExpense	14200	USD
CY2016Q4	mtnb	Increase Decrease In Lease Rental Expense IncreaseDecreaseInLeaseRentalExpense	64000	USD
CY2016Q4	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	43000	USD
	mtnb	Revenue Recognition Milestone Fee On Achieving Sales Threshold RevenueRecognitionMilestoneFeeOnAchievingSalesThreshold	100000	USD
CY2017Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2017Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2017Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	91972323	shares
CY2017Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	91972323	shares
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	58159495	shares
CY2016Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	57593414	shares
CY2017Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	91611531	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	57440685	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	88285929	shares
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	14710119	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	-12028	USD
	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	289102	USD
	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	0	USD
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> </div> <table style="LINE-HEIGHT: 115%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" border="0" cellspacing="0" cellpadding="0"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 38.7pt; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="52"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <strong><font style="FONT-SIZE: 10pt">[4]</font></strong></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <strong><font style="FONT-SIZE: 10pt">Concentration of Credit Risk</font></strong></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><font style="FONT-SIZE: 10pt"> </font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 38.7pt" align="justify"><font style="FONT-SIZE: 10pt">The Company’s financial instruments that are exposed to concentrations of credit risk consist primarily of cash. Cash balances are maintained principally at two major U.S. financial institutions and are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to regulatory limits. At all times throughout the six months ended June 30, 2017, the Company’s cash balances exceeded the FDIC insurance limit. The Company has not experienced any losses in such accounts.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.01150	pure
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.01375	pure
CY2016Q3	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	0.67
CY2016Q3	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	0.70
CY2016Q3	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	1.00
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Description ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription	granted at prices not less than 100% of the fair value
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Outstanding Stock Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum	0.04	pure
CY2017Q2	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	167000	USD
CY2017Q2	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	683000	USD
CY2017Q2	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	707000	USD
CY2017Q2	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	731000	USD
CY2017Q2	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	671000	USD
CY2017Q2	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	2959000	USD
	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	176000	USD
	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	125000	USD
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0	pure
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0	pure
CY2017Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2016Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
	us-gaap	Description Of Lessee Leasing Arrangements Capital Leases DescriptionOfLesseeLeasingArrangementsCapitalLeases	The payments under the leases are accounted for as interest and payments under capital lease using 3 year amortization
	mtnb	Issuance Of Warrants Description IssuanceOfWarrantsDescription	The Company may call the Warrants, other than the Placement Agent Warrants, at any time the common stock trades above $5.00 ( for warrants issued in 2013) or above $ 3.00 (for warrants issued in 2015) for twenty (20) consecutive days following the effectiveness of the registration statement covering the resale of the shares of common stock underlying
CY2014Q2	mtnb	Sharebased Compensation Arrangement By Sharebased Payment Award Increase Of Shares Offering Date SharebasedCompensationArrangementBySharebasedPaymentAwardIncreaseOfSharesOfferingDate	January 1, 2015
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P11M12D
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	30000000	USD
CY2017Q2	mtnb	Estimated Service Cost EstimatedServiceCost	1400000	USD
	mtnb	Stockissuancecostforprivateplacement Stockissuancecostforprivateplacement	0	USD
	mtnb	Stockissuancecostforprivateplacement Stockissuancecostforprivateplacement	71805	USD
	mtnb	Proceeds From Repayments Of Longterm Capital Lease Obligations ProceedsFromRepaymentsOfLongtermCapitalLeaseObligations	-6202	USD
	mtnb	Proceeds From Repayments Of Longterm Capital Lease Obligations ProceedsFromRepaymentsOfLongtermCapitalLeaseObligations	-12028	USD
CY2017Q1	mtnb	Fee On Warrant Exercise Percentage FeeOnWarrantExercisePercentage	0.05	pure
CY2017Q1	mtnb	Non Accountable Epenses NonAccountableEpenses	35000	USD
CY2017Q2	mtnb	Capitalized Leasing Term CapitalizedLeasingTerm	P36M
CY2016Q4	mtnb	Lease Rental Payment LeaseRentalPayment	6400000	USD
	mtnb	Estimated Net Proceeds From Issuances Of Warrants EstimatedNetProceedsFromIssuancesOfWarrants	16741356	USD
	mtnb	Estimated Net Proceeds From Issuances Of Warrants EstimatedNetProceedsFromIssuancesOfWarrants	0	USD
	us-gaap	Use Of Estimates UseOfEstimates	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <table style="LINE-HEIGHT: 115%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" border="0" cellspacing="0" cellpadding="0"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 38.7pt; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="52"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <strong><font style="FONT-SIZE: 10pt">[2]</font></strong></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><strong><font style="FONT-SIZE: 10pt">Use of Estimates</font></strong></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><font style="FONT-SIZE: 10pt"> </font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 38.7pt" align="justify"><font style="FONT-SIZE: 10pt">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 38.7pt" align="justify"><font style="FONT-SIZE: 10pt">Certain accounting principles require subjective and complex judgments to be used in the preparation of financial statements. Accordingly, a different financial presentation could result depending on the judgments, estimates, or assumptions that are used. Such estimates and assumptions include, but are not specifically limited to, those required in the assessment of the impairment of intangible assets, the valuation of Level 3 financial instruments and determination of stock-based compensation.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	49935	USD
	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	31064	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	789705	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-789705	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	0	USD
	us-gaap	Nature Of Operations NatureOfOperations	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 38.7pt; size: 8.5in 11.0in" align="justify"><b><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">NOTE A Nature of Business</font></font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in"> <b><font style="FONT-SIZE: 10pt"> </font></b> <font style="FONT-SIZE: 10pt"> </font></div> <table style="MARGIN-TOP: 0px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0"> <tr style="TEXT-ALIGN: justify; VERTICAL-ALIGN: top"> <td style="WIDTH: 0%"></td> <td style="TEXT-ALIGN: left; WIDTH: 38.7pt"> <div><b>[1]</b></div> </td> <td style="TEXT-ALIGN: justify"> <div><b>Corporate History</b></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 38.7pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt"></font> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 38.7pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">Matinas BioPharma Holdings Inc. (“Holdings”) is a Delaware corporation formed in 2013. Holdings is the parent company of Matinas BioPharma, Inc. (“BioPharma”), and Matinas BioPharma Nanotechnologies, Inc. (“Nanotechnologies,” formerly known as Aquarius Biotechnologies, Inc.), its operating subsidiaries (“Nanotechnologies”, and together with “Holdings” and “BioPharma”, “the Company” or “we” or “our” or “us”). The Company is a development stage biopharmaceutical company with a focus on identifying and developing novel pharmaceutical products.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 38.7pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">On January 29, 2015, we completed the acquisition of Nanotechnologies (the “2015 Merger”), a New Jersey-based, early-stage pharmaceutical company focused on the development of differentiated and orally delivered therapeutics based on a proprietary, lipid-based, drug delivery platform called “cochleate delivery technology.” Following the 2015 Merger, we are a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective broad spectrum antifungal and anti-bacterial therapeutics for the treatment of serious and life-threatening infections, using our innovative lipid-crystal nano-encapsulation drug delivery platform.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in"> <font style="FONT-SIZE: 10pt"> </font></div> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 38.7pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">On September, 13, 2016, the Company completed the closing of an $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">8.0</font> million private placement equity financing. The Company sold to accredited investors an aggregate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1,600,000</font> Series A Preferred Shares at a purchase price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">5.00</font> per share resulting in net proceeds of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">6.9</font> million. Each Series A Preferred Share is convertible into ten shares of common stock based on the current conversion price.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 38.7pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt"></font> </div> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px 0px 0px 38.7pt; FONT: 10pt Times New Roman, Times, Serif" align="justify">On January 13, 2017, the Company completed its tender offer to amend and exercise certain categories of existing warrants. Pursuant to the Offer to Amend and Exercise, an aggregate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 30,966,350</font> warrants were tendered by their holders and were amended and exercised in connection herewith. The gross cash proceeds from such exercises were approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">13.5</font> million and the net cash proceeds after deducting warrant solicitation agent fees and other estimated offering expenses were approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">12.7</font> million.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px 0px 0px 38.7pt; FONT: 10pt Times New Roman, Times, Serif" align="justify"><font style="FONT-SIZE: 10pt">  <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> <table style="MARGIN-TOP: 0px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0"> <tr style="TEXT-ALIGN: justify; VERTICAL-ALIGN: top"> <td style="TEXT-ALIGN: left; WIDTH: 38.7pt"> <div><b>[2]</b></div> </td> <td style="TEXT-ALIGN: justify"> <div><b>Proprietary Products and Technology Portfolios</b></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt">   </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 38.7pt; FONT: 10pt Times New Roman, Times, Serif" align="justify">We leveraged our platform cochleate delivery technology to develop two clinical-stage products that we believe have the potential to become best-in-class drugs. Our lead product candidate MAT2203 is an orally-administered cochleate formulation of a broad spectrum anti-fungal drug called amphotericin B. We are initially developing MAT2203 for the treatment of serious fungal infections as well as the prevention of invasive fungal infections (IFIs) due to immunosuppressive therapy. In early June, 2017 Company reported interim data from NIH-Conducted Phase 2a Clinical Study of Orally-Administered MAT2203 for the Treatment of Chronic Refractory Mucocutaneous Candidiasis. Later that month, the Company reported topline results from our Phase 2 study of MAT2203 in Vulvovaginal Candidiasis</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 38.7pt; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 38.7pt; FONT: 10pt Times New Roman, Times, Serif" align="justify">Our second clinical stage product candidate is MAT2501, an orally administered, encochleated formulation of the broad spectrum aminoglycoside antibiotic amikacin which may be used to treat different types of multidrug-resistant bacteria, including non- tuberculous mycobacterium infections (NTM), as well as various multidrug-resistant gram negative and intracellular bacterial infections. We recently completed and announced topline results from a Phase 1 single escalating dose clinical trial of MAT2501 in healthy volunteers in which no serious adverse events were reported and where oral administration of MAT2501 at all tested doses yielded blood levels that were well below the safety levels recommended for injected amikacin, supporting further development of MAT2501 for the treatment of NTM infections.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2017Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	12000	USD
CY2016Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	13000	USD
CY2017Q2	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	73000	USD
CY2016Q2	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	62000	USD
CY2017Q2	us-gaap	Interest Expense Lessee Assets Under Capital Lease InterestExpenseLesseeAssetsUnderCapitalLease	1194	USD
	us-gaap	Interest Expense Lessee Assets Under Capital Lease InterestExpenseLesseeAssetsUnderCapitalLease	1697	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	47521000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	32227000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0	pure
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0189	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0222	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0115	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.01375	pure

Files In Submission

Name	View Source	Status
0001144204-17-040982-index-headers.html	Edgar Link	pending
0001144204-17-040982-index.html	Edgar Link	pending
0001144204-17-040982.txt	Edgar Link	pending
0001144204-17-040982-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
mtnb-20170630.xml	Edgar Link	completed
mtnb-20170630.xsd	Edgar Link	pending
mtnb-20170630_cal.xml	Edgar Link	unprocessable
mtnb-20170630_def.xml	Edgar Link	unprocessable
mtnb-20170630_lab.xml	Edgar Link	unprocessable
mtnb-20170630_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v471369_10q.htm	Edgar Link	pending
v471369_ex31-1.htm	Edgar Link	pending
v471369_ex31-2.htm	Edgar Link	pending
v471369_ex32-1.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$MTNB
Matinas BioPharma Holdings, Inc. Stock $mtnb

2017 Q2 Form 10-Q Financial Statement

#000114420417040982 Filed on August 08, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MTNB Matinas BioPharma Holdings, Inc. Stock $mtnb

2017 Q2 Form 10-Q Financial Statement

#000114420417040982 Filed on August 08, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MTNB
Matinas BioPharma Holdings, Inc. Stock $mtnb